Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.39 |
| ▸ | NOS1 | P29475 | 3/20 | 0.39 |
| ▸ | NOS2 | P35228 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 11/20 | 0.35 |
| ▸ | BCHE | P06276 | 6/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5155574 | 0.84 | MEN1 (0.43) | NOS3NOS1NOS2ALDH1A1TP53 | |
| SCHEMBL19995820 | 0.81 | NOS3 (0.36) | NOS3NOS1NOS2ALDH1A1TP53 | |
| SCHEMBL23808911 | 0.80 | ACHE (0.44) | NOS3NOS1NOS2ALDH1A1TSHR | |
| SCHEMBL19791796 | 0.78 | ACHE (0.46) | NOS3NOS1NOS2ALDH1A1TSHR | |
| SCHEMBL21722857 | 0.77 | ACHE (0.33) | NOS3NOS1NOS2ALDH1A1TP53 | |
| SCHEMBL13091632 | 0.77 | CYP3A4 (0.34) | NOS3NOS1NOS2ALDH1A1TP53 | |
| SCHEMBL6231710 | 0.75 | ACHE (0.42) | NOS3NOS1NOS2ALDH1A1MEN1 | |
| SCHEMBL20002035 | 0.73 | ALDH1A1 (0.39) | NOS3NOS1NOS2ALDH1A1TP53 | |
| SCHEMBL19830022 | 0.73 | NOS3 (0.45) | NOS3NOS1NOS2TSHRMAPT | |
| SCHEMBL19266204 | 0.73 | NOS3 (0.44) | NOS3NOS1NOS2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570156-B2 | Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2020-02-25 | — | — | US | disclosed |
| EP-3210984-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20180072759-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2018-03-15 | — | — | US | disclosed |
| US-9856274-B2 | Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-02 | — | — | US | disclosed |
| EP-3210984-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2663565-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20160102106-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2016-04-14 | — | — | US | disclosed |
| US-9249162-B2 | Substituted [1,2,4]triazolo[1,5-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140288062-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2014-09-25 | — | — | US | disclosed |
| US-8765760-B2 | [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2663565-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| WO-2012096929-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-19 | — | — | WO | disclosed |
| US-20120178748-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178748-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | NOS3 3194/4885NOS1 4261/4885NOS2 4008/4885 |
| US-20180072759-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | NOS3 3194/4885NOS1 4261/4885NOS2 4008/4885 |
| US-10570156-B2 | Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors | PDE3A, PDE2A, PDE5A | NOS3 460/4885NOS1 268/4885NOS2 567/4885 |
| US-20140288062-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | NOS3 3194/4885NOS1 4261/4885NOS2 4008/4885 |
| US-20160102106-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | NOS3 3194/4885NOS1 4261/4885NOS2 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.